Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study [Rapid Communication]

Conclusion
Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.

Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ou, Ahn, De Petris, Govindan, Yang, Hughes, Lena, Moro-Sibilot, Bearz, Ramirez, Mekhail, Spira, Bordogna, Balas, Morcos, Monnet, Zeaiter, Kim Tags: Rapid Communications, Lung Source Type: research